Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 16, 2013

Sigma-Tau PharmaSource, Aradigm Ink Manufacturing Deal for Respiratory Disease Treatment

  • Sigma-Tau PharmaSource and Aradigm have entered into a broad manufacturing services agreement in which Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin®, Aradigm’s formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.

    Per the agreement, Sigma-Tau PharmaSource will manufacture all product for Aradigm’s Phase III clinical studies and will support the company in the preparation of its submissions to regulatory authorities. Subsequent to market approval, Sigma-Tau PharmaSource will produce the product commercially for patients using Pulmaquin.

    According to Aradigm, the firms have previously worked together on multiple programs, including the manufacturing of Aradigm’s AERx® inhaler dosage forms and all Phase I and Phase II clinical supplies of Aradigm’s inhaled ciprofloxacin formulations.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »